Mereo Biopharma, based in London and founded in 2015, specializes in developing and commercializing innovative therapeutics for rare diseases and cancer. The company addresses the challenges faced by large pharmaceutical firms in resource allocation for drug development, particularly for candidates beyond Phase 2 trials. Mereo has acquired a mid-late stage portfolio of three well-characterized products from Novartis Pharmaceuticals, each backed by robust pre-clinical and proof-of-concept clinical data. The company focuses on transforming patient outcomes through its pipeline of drugs targeting significant unmet medical needs. Mereo leverages its team's expertise in selecting and advancing product opportunities and collaborates with ICON, a leading global contract research organization, to enhance its operational efficiency. Mereo aims to progress its products through critical development milestones before considering partnerships or commercialization, particularly in orphan disease indications.
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.